MT1P3: A Potential Drug Target and Biomarker for Various Diseases

Target Name: MT1P3

NCBI ID: G140851

MT1P3

Other Name(s): C20orf127 | dJ614O4.6 | MTL4 | metallothionein 1 pseudogene 3 | MGC118948 | Metallothionein 1 pseudogene 3

MT1P3: A Potential Drug Target and Biomarker for Various Diseases

MT1P3 (C20orf127) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. The gene is located on chromosome 20 and encodes a protein known as NEDD8-like RNA binding protein 1 (NEDD8-LBP).

NEDD8-LBP is a non-coding RNA molecule that plays a critical role in various cellular processes, including DNA replication, gene expression, and cell signaling. It is composed of a unique alternating between a 7- and 8-nt stem-loop and a 3'-end exon. The 5' end exon is usually exon 1, while the 3' end exon is usually exon 2.

Studies have shown that NEDD8-LBP is involved in various cellular processes, including the regulation of gene expression, DNA replication, and cell signaling. It has been shown to play a role in the development and progression of various diseases, including cancer.

One of the most promising aspects of MT1P3 is its potential as a drug target. The NEDD8-LBP protein has been shown to interact with various signaling pathways, including the PI3K/Akt signaling pathway. This suggests that NEDD8-LBP could be a useful target for inhibiting the activity of these signaling pathways and potentially treating various diseases.

In addition to its potential as a drug target, MT1P3 has also been shown to be a potential biomarker for various diseases. The expression of MT1P3 has been shown to be elevated in various diseases, including cancer. This suggests that MT1P3 could be a useful biomarker for monitoring the effectiveness of various treatments for these diseases.

Another promising aspect of MT1P3 is its potential to target cancer cells specifically. Cancer cells are known to have altered expression of various genes, including NEDD8-LBP. This suggests that MT1P3 could be a useful target for cancer cells, particularly those that are resistant to traditional cancer treatments.

In conclusion, MT1P3 is a gene that has been identified as a potential drug target and biomarker for various diseases. The NEDD8-LBP protein is involved in various cellular processes and has been shown to play a role in the development and progression of various diseases, including cancer. The potential use of MT1P3 as a drug target and biomarker makes it an attractive target for the development of new treatments for these diseases.

Protein Name: Metallothionein 1 Pseudogene 3

The "MT1P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MT1P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets